Bellevue Asset Management successfully concludes integration of Adamant Biomedical Investments

Bellevue Group AG / Bellevue Asset Management successfully concludes integration of Adamant Biomedical Investments . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Integration of Adamant Biomedical Investments completed as planned on April 21, 2015; merger of Adamant Biomedical Investments and Bellevue Asset Management approved by FINMA
  
• Transfer of Adamant's investment fund product range, investment mandates and assets under management of CHF 831 million to Bellevue Asset Management
  
• Total assets under management at Bellevue Asset Management now amount to more than CHF 5.5 billion

Having received regulatory approval from FINMA on April 16, 2015, Bellevue Asset Management AG has merged with Adamant Biomedical Investments AG (Adamant), which was acquired from Zürcher Kantonalbank in September 2014, with effect from April 21, 2015. Upon consummation of the merger, Adamant's investment funds and mandates business with assets of CHF 831 million under management have been transferred to Bellevue Asset Management. This transaction strengthens Bellevue Asset Management's healthcare investment capabilities and product offering in both qualitative and quantitative terms and its leading international position in this business. Bellevue Asset Management now has assets under management of more than CHF 5.5 billion (as of March 31, 2015).

The nine-strong team headed by Dr. Cyrill Zimmermann will additionally assume management responsibility for Bellevue Asset Management's investment fund and mandates business in the healthcare segment. The well-known Adamant brand will be retained at the product level. BB Biotech AG, the flagship product at Bellevue Asset Management, will remain under the management and guidance of the proven team of professionals headed by Dr. Daniel Koller.

"The completion of the merger with Adamant represents another milestone in the corporate development of Bellevue Asset Management and creates interesting growth opportunities, both national and international. At the same time our clients benefit from our enhanced investment competence and a larger product range. Thanks to the very good collaboration with our new colleagues we were able to close the acquisition with this integration both smoothly and swiftly," comments André Rüegg, CEO Bellevue Asset Management.

Contacts:

Media Relations:

André Rüegg, CEO Bellevue Asset Management

Telephone +41 44 267 67 00, Fax +41 44 267 67 01, aru@bellevue.ch

Investor Relations:

Daniel Koller, CFO Bellevue Group                                        

Telephone +41 44 267 67 00, Fax +41 44 267 67 01, ir@bellevue.ch

Bellevue Group

Bellevue Group is an independent Swiss financial boutique listed on the SIX Swiss Exchange. Established in 1993, the company and its approximately 90 employees are specialists in the fields of Brokerage, Corporate Finance and Asset Management. Bellevue Group includes the two subsidiaries Bank am Bellevue and Bellevue Asset Management. The bank boasts strong knowledge of the Swiss stock and bond market and offers independent research opinions and recommendations as well as viable solutions for capital market transactions. Bellevue Asset Management is focused on selected active equity investment strategies in growing markets, in healthcare industries as well as in other special themes such as entrepreneur-led companies.

--- End of Message ---

Bellevue Group AG
Seestrasse 16; Postfach Küsnacht/Zürich Switzerland

WKN: A0LG3Z;ISIN: CH0028422100;